Revvity Launches Signals AI to Turn R&D Data Into Natural-Language Decisions

Revvity launched Signals AI on June 22, 2026, a native agentic framework embedded within its Signals One platform that allows scientists to query, interpret and act on research and development (R&D) data using natural language. The Massachusetts-based health science company, which reported $2.9 billion in revenue for 2025, said the launch marks a shift in how its scientific software handles knowledge.

“The addition of the Signals AI capabilities within Revvity’s Signals One platform reflects a fundamental shift in how scientists work with R&D knowledge,” said Kevin Willoe, president of Revvity Signals Software.

According to the company, Signals AI introduces an intelligence layer into Signals One that lets researchers engage directly with connected R&D data across experiments, instruments, applications and systems. The challenge for scientific organisations is no longer collecting data but converting it into decisions and action, the company said.

What the Platform Does

Signals AI grounds its outputs in structured scientific data, domain ontologies and validated scientific algorithms. This design, the company said, produces traceable, scientifically relevant responses delivered through natural language, alongside interactive views of molecules, sequences, experimental results and connected knowledge.

The company also mentioned that the framework allows scientists to dynamically reformat existing knowledge for any purpose within their existing workflows, without switching between systems.

Willoe added that while traditional scientific software limits data to predefined dashboards and workflows, Signals AI introduces a model where researchers use natural language to interact directly with organizational knowledge. By combining adaptive AI reasoning with trusted scientific intelligence, the platform accelerates insights without compromising research rigor.

According to the company, Signals AI is designed to transform scientific software from a system of record into what it described as a system of scientific understanding, helping researchers move from data to insight and from insight to action. The AI platform serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments in more than 160 countries.

Select capabilities of Signals AI are available as of the announcement date, the company said, with additional capabilities expected to be released and enhanced in the coming weeks. The launch follows a series of AI additions to the Signals platform.

In December 2025, Revvity introduced Signals Xynthetica, an artificial intelligence-augmented design platform for molecular and materials discovery. In January 2026, the company announced a collaboration with Eli Lilly and Company to make Lilly's predictive models available through the Signals platform. Signals BioDesign, a cloud-native molecular cloning solution, followed in April 2026.